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Abstract
Background: Penicillin resistance in Streptococcus pneumoniae is mediated by a mosaic of genes encoding altered
penicillin-binding proteins (PBPs). Nonetheless, S. pneumoniae has also developed non-PBP mechanisms implicated
in penicillin resistance. In this study, whole genome sequencing of resistant organisms was used to discover
mutations implicated in resistance to penicillin.
Results: We sequenced two S. pneumoniae isolates selected for resistance to penicillin in vitro. The analysis of the
genome assemblies revealed that six genes were mutated in both mutants. These included three pbp genes, and
three non-pbp genes, including a putative iron permease, spr1178. The nonsense mutation in spr1178 always
occurred in the first step of the selection process. Although the mutants had increased resistance to penicillin, the
introduction of altered versions of PBPs into a penicillin-susceptible strain by sequential transformation led to
strains with a minimal increase in resistance, thus implicating other genes in resistance. The introduction by
transformation of the non-PBP recurrent mutations did not increase penicillin resistance, but the introduction of
the nonsense mutation in the putative iron permease spr1178 led to a reduced accumulation of reactive oxygen
species following exposure to penicillin and to other bactericidal antibiotics as well.
Conclusions: This study indicates that the selection of resistance to penicillin in S. pneumoniae involves the
acquisition of mutations conferring tolerance to the antibiotic-induced accumulation of oxidants, which translates
into an increased survival that putatively enables the selection of major resistance determinants such as mutations
in PBPs.
Background
Streptococcus pneumoniae is an important pathogen of
the respiratory tract causing community-acquired pneu-
monia worldwide [1]. It is also an etiological agent of
otitis media, sepsis, and meningitis in adults and chil-
dren and constitutes a significant health threat. Penicil-
lin, a ß-lactam antibiotic, has long been the mainstay
against pneumococcal infections but its efficacy is threa-
tened by the rapid dissemination of penicillin non-sus-
ceptible clones worldwide, the prevalence of which
varies between countries (reviewed in [2,3]).
b-Lactams are bactericidal antibiotics that inhibit the
synthesis of the peptidoglycan layer of bacterial cell
walls by inactivating penicillin-binding proteins (PBPs),
a group of membrane-associated cytoplasmic proteins
involved in the assembly of peptidoglycan and whose
inhibition results in growth arrest and lysis. Resistance
to ß-lactam antibiotics in clinical isolates of S. pneumo-
niae occurs through the acquisition of mosaic genes
encoding altered PBPs. The mosaic genes encode PBP
variants of lower antibiotic binding affinities and are the
result of intra- and interspecies gene transfer events
involving related streptococcal species [4,5]. Although S.
pneumoniae contains six PBPs, variants of PBP2x,
PBP2b and PBP1a are considered the most relevant to
penicillin resistance. Furthermore, the acquisition of
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a prerequisite for PBP1a variants to confer high-level
resistance to ß-lactams [6,7]. PBP2x has the highest affi-
nity for penicillin in S. pneumoniae and a variety of
amino acid substitutions interfering with the polarity
and charge distribution in the vicinity of the active site
have been implicated in poor antibiotic binding and
resistance [8,9].
Mutations in PBPs are not the sole contributors of
resistance to ß-lactams in S. pneumoniae, and evidence
for some non-PBP resistance mechanisms is available.
Indeed, the cell wall of penicillin non-susceptible isolates
is often highly enriched in branched chain muropep-
tides, a phenomenon linked to mosaic alleles of the
murM gene [10,11]. Furthermore, mutations in a pepti-
doglycan N-acetylglucosamine deacetylase [12], a pepti-
doglycan O-acetyltransferase [13], a putative
glycosyltransferase [14], a serine threonine kinase [15], a
histidine protein kinase part of a two-component signal
transducing system [16], or in a phosphate ABC trans-
porter [17] have been implicated in resistance to ß-
lactams.
Global approaches such as whole genome sequencing
(WGS) of antibiotic-sensitive and -resistant isolates are
powerful tools that are now readily available for use in
determining the mode of action of antimicrobial drugs
and the mechanisms involved in resistance [18-20]. We
report here the WGS of two independent S. pneumoniae
mutants selected for in vitro resistance to penicillin and
the identification of known and new mutations involved
in resistance.
Results
Selection and whole-genome sequencing of S.
pneumoniae penicillin non-susceptible mutants
Two independent penicillin-resistant mutants of S.
pneumoniae R6 and S. pneumoniae 1974 were selected
by stepwise penicillin increments until they reached a
final penicillin minimum inhibitory concentration (MIC)
of 2 μg/ml. It has not been possible to obtain mutants
resistant to higher levels. The penicillin MICs of the
wild-type (WT) progenitors were 0.023 μg/ml and 0.016
μg/ml for the S. pneumoniae R6 and 1974 lineages,
respectively. The most highly resistant isolates were
named R6M1 and R6M2 or 1974M1 and 1974M2
depending on whether they were derived from the S.
pneumoniae R6 or 1974 background, respectively. All
four penicillin-resistant strains were cross resistant to
the cefotaxime but remained susceptible to erythromy-
cin, tetracycline, linezolid, kanamycin and ciprofloxacin
(Table 1).
We conducted WGS of R6M1 and R6M2 in order to
elucidate the genetic events associated with the penicil-
lin-resistant phenotype. The genome of R6M1 was
sequenced by using the comparative genome sequencing
technology developed by NimbleGen, which relies on
the use of tiled DNA microarray hybridizations to
rapidly survey entire microbial genomes and to identify
the location of SNPs, insertions, or deletions [19,20].
The comparative genome sequencing of R6M1 and WT
parent allowed the identification of 26 mutations in
R6M1 (Table 2) that were further confirmed by PCR
amplification and conventional DNA sequencing. The
genome of R6M2 was sequenced using the massively
parallel 454 Life Science (Roche) GS-FLX DNA sequen-
cing platform, which generated a genome assembly of
28× coverage, with 97% of the reads assembled into 78
large contigs. Comparative sequence analysis of R6M2
and its R6 WT parent revealed 52 mutations (Table 2)
that were confirmed by PCR amplification and conven-
tional DNA sequencing. The mutations can also be seen
as part of circular schematic maps (Additional file 1).
The WGS of R6M1 and R6M2 identified a total of 40
genes that have acquired a non-synonymous mutation
in at least one of the mutants (Table 2). Of these, six
genes were mutated in both mutants (Table 3). These
included three PBP-encoding genes, pbp2x, pbp2b and
pbp1a, in which a total of 14 missense mutations and
one nonsense mutation have been observed in R6M1
and R6M2 (Table 3). The targeted sequencing of the six
common genes in the 1974M1 and 1974M2 strains
identified another 14 missense substitutions in PBP2x
and PBP2b and nonsense mutations in PBP1a (Table 3).
The T451A and G435S amino acid substitutions in
PBP2b and the R384G, V518I and Q552E substitutions
in PBP2x were shared by some of the mutants derived
from R6 and 1974 (Table 3). The three other non-PBP-
encoding genes identified by WGS mutated in both R6
mutants (although not always at the same position)
were the ABC protein PstB (spr1254), the DNA mis-
match repair protein HexA (spr1888) and a hypothetical
protein (spr1178). Interestingly, the analysis of targeted
PCR fragments from 1974M1 and 1974M2 revealed that
the same nonsense mutation occurred at position 28 of
the spr1178 protein in all mutants but no mutations
Table 1 Susceptibility levels of S.pneumoniae isolates
S. pneumoniae MIC (μg/ml)
strain PG CT EM CI KM TC LZ
R6-WT 0.023 0.023 0.125 0.5 25 0.125 0.38
R6M1 2.0 0.75 0.125 0.5 25 0.125 0.38
R6M2 2.0 0.75 0.125 0.5 25 0.125 0.38
1974-WT 0.016 0.023 0.125 0.5 25 0.125 0.75
1974M1 2.0 1.5 0.125 0.5 25 0.125 0.75
1974M2 2.0 2.0 0.125 0.5 25 0.125 0.75
Results are the average of at least three independent measurements. CI,
ciprofloxacin; CT, cefotaxime; EM, erythromycin; KM, kanamycin; LZ, linezolid;
PG, penicillin G; TC, tetracycline; WT, wild-type.
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S. pneumoniae strain
M1 M2
Locus
name
Putative identification Nucleotide
change
Amino acid
change
Nucleotide
change
Amino acid
change
spr0032 DNA polymerase I A107G H36R
spr0041 Transposase (orf2) GAA31AAC E11N
GCTCG36TCTCA K12N;D14N
T63A SYN
GG204TA D69Y
spr0113 Hypothetical protein A4G K2E
spr0121 Surface protein PspA precursor A4G N2D
T1374C SYN
spr0160 DNA mismatch repair protein (Hex B) G752A S251N
spr0182 Hypothetical protein G82insertion frame shift
spr0284 Alpha-xylosidase T1107C SYN
spr0304 Penicillin-binding protein 2x A1150G R384G A842C Q281P
G1552T V518L C1106T A369V
C1654G Q552E A1150G R384G
C1276T R426C
G1552A V518I
spr0329 Penicillin-binding protein 1a G1630A G544R G1233A W411*
spr0376 Conserved hypothetical protein T207C SYN
spr0422 Hypothetical protein C391T Q131*
spr0475 Conserved hypothetical protein G318C L106F
spr0509 Phenylalanyl-tRNA synthetase beta chain C105T SYN
spr0598 GTP-binding protein (TypA/BipA) (tyrosine phosphorylated
protein A)
C905T P302L
spr0666 ABC transporter ATP-binding protein - cell division (FtsE) C410T P137L
spr0764 30S Ribosomal protein S1 G1173A M391I
spr0776 D-Alanyl-D-alanine carboxypeptidase C287T A96V
spr0866 Dihydroorotate dehydrogenase C575T P192L
spr0878 Exoribonuclease R G280T G94W
spr0895 Conserved hypothetical protein G134C R45T
spr0917 Citrulline cluster-linked gene C59T A20V
spr0934 ABC transporter substrate-binding protein - iron transport G486A W162*
spr1041 Hypothetical protein C648T SYN
spr1043 Conserved hypothetical protein C109T P37S C105T SYN
spr1092 tRNA pseudouridine 5S synthase C210T SYN
spr1127 Ribonuclease III A228G SYN C554T T185I
spr1152 LicD G692T P231L
spr1166 Signal recognition particle (Fifty four homolog) C139T P47S
spr1178 Hypothetical protein C82T Q28* C82T Q28*
spr1186 N-Acetylneuraminate lyase subunit, truncation T603C SYN
G620A G207D
GAC660AAT T221I
AA689CG E230A
T696A SYN
spr1224 Conserved hypothetical protein T564C SYN
spr1240 Alanyl-tRNA synthetase A139G T47A
spr1254 ABC transporter ATP-binding protein-phosphate transport
(PstB)
G499A G167S C614T T205I
spr1260 Conserved hypothetical protein T597C SYN
spr1272 N-Acetylglucosamine-6-phosphate isomerase G385A G129R
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(Table 3).
Reconstruction of resistance by transformation of
mutated PBPs
Transformation experiments of S. pneumoniae R6 WT
with pbp genes amplified from either the R6M1 or
R6M2 mutants were conducted to assess the contribu-
tion of the different PBP mutations to penicillin resis-
tance. The analysis of the PBP sequences at the different
levels of R6M1 and R6M2 selection (0.06, 0.125, 0.25,
0.5, 1.0 and 2.0 μg/ml penicillin G (PG)) revealed a step-
wise selection of PBP mutations (Additional file 2). The
analysis of the chronological appearance of PBP muta-
tions in R6M2 revealed that the progression towards
penicillin resistance began with the Q281P substitution
in PBP2x followed by the T451A substitution in PBP2b.
The other PBP2x mutations happened sequentially as
the level of resistance to penicillin increased and the
remaining PBP2b and PBP1a mutations were only
selected at high concentration of penicillin (Additional
file 2). The pbp2x, pbp2b and pbp1a genes were ampli-
fied from R6M1 and R6M2 genomic DNA and were
sequenced to confirm the presence of the mutations
described in Table 3. Because of the order of mutation
appearance (Additional file 2), we introduced sequen-
tially the R6M1 mutations by first transforming the PCR
fragment for pbp2x into the recipient S. pneumoniae R6
WT. The selection of transformants with 0.03 μg/ml
penicillin enabled the transfer of the three PBP2x muta-
tions found in R6M1 (R384G, V518L, Q552E). This
transformant, named R6
2x-M1, had a penicillin MIC of
0.06 μg/ml (Table 4). In a second round of transforma-
tion, the pbp2b gene from R6M1 was used as donor
DNA for the transformation of the recipient R6
2x-M1.
Selection with 0.06 μg/ml penicillin yielded second-level
transformants that acquired the two PBP2b mutations
of R6M1 (D415E, G665D) and these transformants,
called R6
2x2b-M1, had a penicillin MIC of 0.125 μg/ml
(Table 4). All attempts to introduce pbp1a mutations
failed. We used a similar approach for R6M2 but in the
first level transformation we pooled the pbp2x, 2b and
1a P C Rf r a g m e n t sd e r i v e df r o mR 6 M 2t h a tw e r et r a n s -
formed into R6WT. The selection of transformants with
0.03 μg/ml penicillin enabled the transfer of only the
PBP2x mutations Q281P, A369V and R384G, but not
Table 3 Genes mutated in at least two S.pneumoniae penicillin resistant mutants
S. pneumoniae strains
Locus name R6M1 R6M2 1974M1 1974M2
PBP1a G544R W411* E248* E158*
PBP2x R384G,V518I, Q552E Q281P, A369V, R384G, R426C, V518I F388L, Q552E, V573L, V587L, G601V A507V, P535L, Q552E
PBP2b D415E, G665D A395V, G435S, T451A G435S, T451A T431D, T451A, L492F, Q633E
Spr1178 Q28* Q28* Q28* Q28*
Spr1254 G167S T205I WT WT
Spr1888 T728I Q326* WT WT
Mutations are shown as amino acid changes with their corresponding position in the protein. Asterisks indicate nonsense mutations. Mutations that are common
in at least two strains are in bold.
Table 2 Mutations identified in R6M1 and R6M2 penicillin-resistant mutants (Continued)
spr1384 UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-L-lysine ligase G996A M332I
spr1423 Conserved hypothetical protein A673G M225V
spr1453 Major facilitator superfamily transporter T91C F31L
spr1465 Conserved hypothetical protein G419A G140E
spr1517 Penicillin-binding protein 2b C1245A D415E C1184T A395V
C1528A G665D G1303A G435S
A1351G T451A
spr1587 Conserved hypothetical protein C568T SYN
spr1703 ABC transporter ATP-binding protein - oligopeptide transport C575A P192Q
spr1706 ABC transporter membrane-spanning permease -
oligopeptide transport
T399deletion frameshift
spr1862 Competence protein A51G SYN
spr1886 Degenerate transposase A314G *105W
spr1888 DNA mismatch repair protein (HexA) C2183T T728I C976T Q326*
spr1991 Glycerol kinase GG78TT E27*
Asterisks and SYN indicate nonsense mutations and synonymous mutations, respectively.
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attempts. The transformants, named R6
2x-M2,h a da
penicillin MIC of 0.06 μg/ml (Table 4). In a second
round of transformation, a pool of pbp2b and pbp1a
PCR fragments from R6M2 was used as donor DNA in
the transformation of the recipient R6
2x-M2.S e l e c t i o n
with 0.06 μg/ml penicillin yielded second-level transfor-
mants that acquired the three PBP2b mutations of
R6M2 (T451A, G435S and A395V) but retained an
unaltered allele of pbp1a. These transformants, named
R6
2x2b-M2, had a penicillin MIC of 0.125 μg/ml (Table
4). Several attempts failed to introduce the PBP1a muta-
tion of R6M2 into the R6
2x2b-M2 line.
Given that PBP1a variants are usually associated with
high level b-lactam resistance, we assessed the role of the
R6M2 pbp1a point mutation by transforming the R6
2x2b-
M2 line with the rpsL Janus cassette [21]. This required
the introduction of a mutated rpsL gene to obtain a R6
transformed cell resistant to streptomycin (see Materials
and methods). The integration of the PBP1a Janus cas-
sette (Additional file 3) into an R6
2x2b-M2 streptomycin-
resistant recipient (R6
SmR, 2x2b-M2) was selected under
kanamycin pressure and yielded streptomycin-sensitive
and kanamycin-resistant R6
2x2b-M2, 1a::janus transformants.
The replacement of the Janus cassette from R6
2x2b-M2, 1a::
janus was performed in a second round of transformation
with a pbp1a fragment amplified from R6M2 flanked by
3 kb of upstream and downstream regions (Additional
files 3 and 4). The selection under streptomycin pressure
yielded the streptomycin-resistant and kanamycin-sensi-
tive R6
SmR, 2x2b1a-M2 transformants that acquired the
pbp1a allele of R6M2. However, although the targeted
sequencing of pbp1a in R6
SmR, 2x2b1a-M2 confirmed the
acquisition of the R6M2 nonsense mutation at position
411 of the protein, this strain had penicillin resistance
levels identical to those of the R6
2x2b-M2 line (MIC 0.125
μg/ml; Table 4). We tested further the role of PBP1a in
resistance by introducing a wild-type copy of the gene in
the penicillin-resistant mutant R6M1. The co-transfor-
mation of a pbp1a fragment amplified from S. pneumo-
niae R6 WT with a rpsL fragment conferring
streptomycin resistance into R6M1 yielded the
R6M1
SmR,1a-wt transformant that harbored a WT pbp1a
allele. Interestingly, the R6M1
SmR, 1a-wt transformant
became two times more sensitive to penicillin (PG MIC
1.0 μg/ml) than its parent (Table 4).
Table 4 Minimal inhibitory concentrations to penicillin of Streptococcus pneumoniae mutants and transformants
Strain or
transformant
Description MIC to PG
(μg/ml)
a
R6 Wild type 0.023
CCRI1974 S. pneumoniae, sensitive clinical isolate 0.023
R6M1 R6 clone selected in vitro for PG resistance 2.0
R6M2 R6 clone selected in vitro for PG resistance 2.0
1974M1 1974 clone selected in vitro for PG resistance 2.0
1974M2 1974 clone selected in vitro for PG resistance 2.0
CP1250 S. pneumoniae that contains a spontaneous mutation in the rpsL gene that confers resistance to SM
R6
2x-M1 R6-WT transformed with pbp2x PCR fragments from R6M1 (contains all three missense mutations present in
PBP2x of R6M1)
0.06
R6
2x-M2 R6-WT transformed with pbp2x PCR fragments from R6M2 (contains just three mutations - Q281P, A369V, R384G
- out of five mutations present in PBP2x of R6M2)
0.06
R6
2x2b-M1 R6
2x-M1 transformed with pbp2b PCR fragments from R6M1 so all missense mutations present in PBP2b of R6M1
transformed into this transformant
0.125
R6
2x2b-M2 R6
2x-M2 transformed with pbp2b PCR fragments from R6M2 so all missense mutations present in PBP2b of R6M2
transformed into this transformant
0.125
R6
2x2b-M2, 1a::Janus R6
2x2b-M2 knocked out in pbp1a by Janus cassette, KM
RSM
S 0.125
R6
SmR, 2x2b1a-M2, R6
2x2b-M2, 1a::Janus subjected to second step transformation with pbp1a of the Janus cassette with pbp1a of
R6M2, KM
SSM
R
0.125
R6
SmR, 2x2b1a,
spr1178-M2,
R6
2x2b1a-M2 transformed with spr1178 PCR fragments from R6M2 (contains a Q28* nonsense mutation in
spr1178), SM
R
0.125
R6
2x2b,spr1254-M2 R6
2x2b-M2 transformed with pstB PCR fragment from R6M2 (contains a T205I mutation in PstB) 0.125
R6
2x2b, spr1254,
spr1178-M2
R6
2x2b-M2 transformed with spr1178 and pstB PCR fragments from R6M2 (contains the substitutions Q28* in
spr1178 and T205I in PstB)
0.125
R6M1
SmR,1a-WT R6M1 co-transformed with a pbp1a PCR fragment from R6-WT and a rpsL streptomycin resistance marker, SM
R 1.0
R6
ko in spr1178 R6-WT knocked out in spr1178, CM
R 0.023
R6
ko in spr1254 R6-WT knocked out in spr1254, KM
R 0.023
R6
spr1888::janus R6-WT knocked out in spr1888 by Janus cassette, KM
RSM
S 0.023
aResults are the average of at least three independent measurements. Asterisks indicate nonsense mutations. PG, penicillin; KM, kanamycin; SM, streptomycin.
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antibiotic-induced oxidants
In addition to the mutations in pbp genes, the WGS
highlighted three genes that were mutated in both the
R6M1 and R6M2 mutants (spr1178, spr1254 and
spr1888) but only spr1178 was also mutated in 1974M1
and 1974M2. Although an increased expression of the
PstB ABC transporter subunit (spr1254) had previously
been associated with penicillin resistance [17], its inacti-
vation by insertional duplication mutagenesis in S. pneu-
moniae R6 WT did not translate into increased
penicillin tolerance (Table 4). Similarly, the independent
inactivation of spr1178 or spr1888 in a WT background
had no effect on the level of penicillin susceptibility
(Table 4). Given that the nonsense mutation in spr1178
had been acquired in every penicillin-resistant mutant
analyzed, we tested whether this recurrence required a
background of altered PBPs in order to confer resis-
tance. Again, neither the independent transformation of
the mutated versions of spr1178 and spr1254 into
R6
SmR, 2x2b1a-M2 and R6
2x2b-M2 recipients nor the simul-
taneous transformation of the spr1178 and spr1254
mutations into an R6
2x2b-M2 recipient altered the peni-
cillin susceptibility of the transformants (Table 4).
Spr1178 encodes a protein of 192 amino acids with
one predicted transmembrane domain that was categor-
ized as part of the DUF3347 family of functionally
uncharacterized proteins by Pfam analysis. However, a
BLAST analysis for spr1178 homologues in different
Streptococcus species revealed several proteins annotated
as Fe
2+/Pb
2+ permeases with at least 70% identity.
Indeed, spr1178 had 86.9% and 86.7% similarity with a
putative iron permease of the FTR1 family [22] from
Streptococcus gordonii [23] and Streptococcus mitis
ATCC6249, respectively, and 94% identity with a puta-
tive high-affinity Fe
2+/Pb
2+ permease from S. pneumo-
niae 670-6B, S. pneumoniae CDC3059-06 and S.
pneumoniae P1031. Intriguingly, the bactericidal activity
of antibiotics like b-lactams has recently been linked to
the iron-dependent accumulation of reactive oxygen
species (ROS) [24]. Since spr1178 has a predicted iron
permease function, we sought to determine whether the
acquisition of the nonsense mutation in spr1178 could
translate into decreased accumulation of ROS following
exposure to penicillin. Using the dichlorofluorescein dia-
cetate (DCF-DA) dye, whose fluorescence intensity is
proportional to the levels of ROS, we showed that sub-
inhibitory concentrations of penicillin induced a greater
time-dependent increase in ROS accumulation in a S.
pneumoniae R6
SmR, 2x2b1a-M2 background than in cells in
which the spr1178 nonsense mutation was introduced
(Figure 1a). Similarly, penicillin induced a greater accu-
mulation of ROS in R6 WT in comparison to a R6 WT
strain in which spr1178 was disrupted (data not shown).
We next tested whether this was a more general feature
of bactericidal antibiotics and we found that ciprofloxa-
cin (Figure 1b) and kanamycin (Figure 1c) also induced
significantly more ROS in cells harboring an unaltered
spr1178 gene. The time-dependent accumulation of
ROS was a specific feature of bactericidal antibiotics,
since the bacteriostatic antibiotics chloramphenicol (Fig-
ure 1d) and tetracycline (Figure 1e), respectively, failed
to induce ROS even in the presence of a WT version of
spr1178 and only induced a slight accumulation of ROS
that was not correlated to the functional status of
spr1178.
Growth kinetics revealed that penicillin resistance
conferred a fitness cost to R6M1 (Figure 2b) and R6M2
(data not shown). The acquisition of PBP2x, 2b and 1a
mutations was not associated with this growth defect, as
the growth of the R6
SmR, 2x2b1a-M2 transformant was not
altered compared to S. pneumoniae R6 WT (Figure 2a).
In contrast, the introduction of a nonsense mutation in
spr1178 conferred a fitness cost, as the growth of the
R6
SmR, 2x2b1a, spr1178-M2 transformant was altered com-
pared to its R6
SmR, 2x2b1a-M2 parent or to S. pneumonaie
R6 WT (Figure 2a). Similarly, the introduction of a WT
spr1178 allele restored the fitness of R6M1, although
the growth defect could not be completely reverted (Fig-
ure 2b).
Discussion
Whole genome sequencing of sensitive and resistant
organisms is a powerful tool for understanding the biol-
ogy of resistance mechanisms [18,19,25-27]. We
sequenced two independent mutants selected for peni-
cillin resistance in vitro to concentrate on recurrent
mutations, a strategy proven to be useful [19]. Resis-
tance to b-lactams in S. pneumoniae clinical isolates was
shown to be a complex process involving the acquisition
of PBP variants of low antibiotic affinity by intra- and
interspecies gene transfer events from related strepto-
coccal species [4,5]. Most PBP mutations directly
involved in resistance were shown to alter the polarity
and charge distribution around the catalytic cleft of the
proteins. Indeed, the G552E substitution located in the
vicinity of the active site of PBP2x [28] is a major deter-
minant of b-lactam resistance [29-31] by inducing a
decreased acylation efficiency to the protein [31]. Inter-
estingly, several PBP2x mutations have been selected in
our R6 and 1974 penicillin-resistant mutants, with every
resistant strain except for R6M2 having acquired the
Q552E substitution (Table 3). Other PBP2x mutations
that have been specifically selected in at least one of our
mutants include the A369V substitution in R6M2 that
was previously reported to be one of the six PBP2x
mutations responsible for the b-lactam resistance of S.
pneumoniae clinical isolates [32] and the G601V
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indirectly affect the active site of PBP2x by introducing
a bulkier side chain involved in topological alterations of
the catalytic cleft [8]. The F388L substitution selected in
1974M1 was shown to be one of the three substitutions
responsible for cefotaxime resistance in a S. pneumoniae
clinical isolate [8]. The F388L substitution is in the core
of a hydrophobic niche close to the catalytic serine,
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Figure 1 Nonsense mutation in spr1178 and reduced accumulation of reactive oxygen species induced by bactericidal antibiotics.
Drug-induced reactive oxygen species accumulation in S. pneumoniae. The DCF-DA fluorescence signals of the S. pneumoniae R6
SmR, 2x2b1a-M2
(green bars) and R6
SmR, 2x2b1a, spr1178-M2 (yellow bars) transformants following exposure to (a) 0.1 μg/ml penicillin, (b) 4.0 μg/ml ciprofloxacin, (c)
400.0 μg/ml kanamycin, (d) 6.0 μg/ml chloramphenicol, and (e) 0.25 μg/ml tetracycline were measured prior to antibiotic exposure (time zero)
and 1 hour, 2 hours, and 3 hours following addition of the antibiotics. The DCF-DA fluorescence signals of the S. pneumoniae R6
SmR, 2x2b1a-M2
(blue bars) and R6
SmR, 2x2b1a, spr1178-M2 (orange bars) transformants untreated cultures measured at each time point are indicated as control.
Results are the average of at least three independent experiments. RFU, relative fluorescence units.
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Page 7 of 12along with the adjacent S389L change frequently
observed in resistant isolates [29], and could be involved
in conformational alterations of the catalytic cleft.
Finally, other PBP2x mutations identified in our penicil-
lin-resistant strains probably have more indirect roles in
resistance, like the R384G and R426C substitutions
selected in both R6 mutants. These substitutions have
also been found in a previously described series of
laboratory-derived cefotaxime-resistant mutants [33].
Reconstruction of resistance by the stepwise introduc-
tion of PBP mutations into a R6 penicillin susceptible
background revealed an ordered appearance of muta-
tions first in pbp2x,t h e ni npbp2b and finally in pbp1a.
Although the R426C and V518I substitutions in PBP2x
only appeared at the third and fifth level of R6M2 selec-
tion (Additional file 2), transformation experiments
failed at introducing these PBP2x substitutions. The
R426C substitution was previously suggested to act as a
compensatory mutation that requires a specific genetic
background in order to be effective [8], which could
provide a plausible explanation to our failure to transfer
this mutation into the R6
2x-M2 transformant. PBP1a var-
iants have been previously shown to confer high-level
penicillin resistance only in the presence of low affinity
PBP2x [34,35] and/or PBP2b [35]. In our study, how-
ever, the introduction of the PBP1a nonsense mutation
from R6M2 into the R6
2x2b-M2 line failed to increase the
level of resistance to penicillin. It also appeared that a
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Figure 2 Nonsense mutation in spr1178 and growth defect in penicillin-resistant S. pneumoniae. (a) The growth kinetics of S. pneumoniae
R6 wild-type, S. pneumoniae R6
SmR, 2x2b1a-M2 and S. pneumoniae R6
SmR, 2x2b1a, spr1178-M2 was followed by measuring the optical density of the
cultures every hour for a 20-hour period. (b) The reversion of the spr1178 nonsense mutation to a wild-type sequence decreased the growth
defect of the R6M1 mutant. Results are the average of at least three independent measurements.
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for PBP1a to participate in resistance as the reversion of
its mutation in R6M1 resulted in a twofold decrease in
resistance (Table 4).
In previously characterized laboratory-derived penicil-
lin and cefotaxime-resistant mutants [36], PBP variants
associated with resistance occurred late during the selec-
tion process [37,38], suggesting that the initial increase
in resistance during the first steps of selection involves
non-PBP mutations. Similarly, the transfer of R6M2 PBP
mutations to a penicillin-susceptible strain did not allow
it to reach the resistance level of the parent mutant
R6M2. Together, this implies that other mutations are
probably involved in resistance. The analysis for recur-
rent mutations in our panel of resistant strains pin-
pointed a nonsense mutation in the putative iron
permease spr1178 that occurred early during the selec-
tion process, before any PBP mutations could be
selected (with the exception of the Q281P substitution
in R6M2) (Additional file 2). It has recently been argued
that bactericidal antibiotics, regardless of their primary
targets, kill bacteria by inducing alterations in iron
homeostasis, ultimately leading to the accumulation of
hydroxyl radicals through the Fenton reaction [24]. Sig-
naling events implicating the envelope stress-response
and redox-responsive two-component systems were also
found to be key players in triggering hydroxyl radical
formation [39]. Although iron-sulfur clusters were initi-
ally implicated as the source of iron [24,40], the inacti-
vation of TonB in Escherichia coli revealed that
exogenous iron can also be implicated in the hydro-
xyurea-induced accumulation of ROS [41]. In this study,
we have shown that three classes of bactericidal drugs,
penicillin, ciprofloxacin and kanamycin, stimulate a
greater production of ROS in the presence of a func-
tional version of spr1178. Bacteriostatic antibiotics like
tetracycline and chloramphenicol failed to induce ROS
irrespective of the functional status of spr1178. Even
though the transformation of the spr1178 nonsense
mutation under a background of mutated PBPs did not
reveal a direct role in resistance to penicillin, its early
inactivation could have provided increased protection
against the accumulation of ROS during the selection of
resistance by potentially decreasing the availability of
free iron. Moreover, the R6M2 mutant further harbors a
nonsense mutation in another putative iron uptake sys-
tem (spr0934; Table 2), which could potentiate the pro-
tective effect conferred by the spr1178 inactivation. The
analysis of a panel of five penicillin non-susceptible clin-
ical isolates failed to show similar nonsense mutations
in spr1178 (data not shown), but this might in part be
explained by the obvious growth defect associated with
the acquisition of this mutation (Figure 2). It is salient
to point out that the exposure to sublethal
concentrations of bactericidal antibiotics was shown to
induce a decreased expression of iron uptake systems in
Pseudomonas aeruginosa [42] and S. pneumoniae [37],
so similar gene expression alterations could also poten-
tially occur in clinical isolates to prevent the accumula-
tion of ROS during the early steps of resistance
selection, instead of more drastic events like nonsense
mutation as observed in isolates selected in vitro.
Our comparative genomic approach revealed that the
selection for penicillin resistance in S. pneumoniae fre-
quently involves the acquisition of a nonsense mutation
in a putative iron transport system that increases the
tolerance to antibiotic-induced accumulation of ROS.
This tolerance should lead to an increased survival that
putatively allows the selection of more important resis-
tance determinants, such as the sequential accumulation
of point mutations in PBPs.
Conclusions
This study indicates that, for in vitro isolates, mutations
in PBPs are not sufficient to achieve high level resis-
tance to penicillin. Our study also reveals that penicillin
kills cells by producing ROS, possibly through the Fen-
ton reaction since less ROS are produced in resistant
mutants in which a putative iron transporter is mutated.
The whole genome sequencing data further revealed
other mutations that were acquired by at least one
mutant and we propose that some of these, or a combi-
nation of mutations, could be associated with penicillin
resistance along with mutations in PBPs.
Materials and methods
Bacterial strains and culture conditions
All strains used in this study are listed in Table 4. Pneu-
moccoci were grown as previously described [19].
Clones of the S. pneumoniae R6 laboratory strain and
the clinical isolate S. pneumoniae CCRI-1974 [19] were
used for the laboratory-induced selection of penicillin
resistance. The selection of resistance was performed on
Zybalski plates containing concentration gradients of PG
as described previously for other drugs [43]. For subcul-
turing, colonies were picked in the area of highest anti-
biotic concentrations and streaked onto agar plates
containing either the same concentration of antibiotic or
a gradient of increased antibiotic concentrations. The
MIC of the resistant cells isolated from the plates with
the highest concentrations of antibiotic was determined
to confirm the resistance phenotype. Five selection
cycles were required to obtain the highly resistant M1
and M2 mutants for each strain.
Antibiotic susceptibility
Antibiotic susceptibilities were determined with E-test
strips (AB bioMérieux, Stockholm, Sweden) on Müller-
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using the manufacturer’si n s t r u c t i o n s .T h eM I C sw e r e
further confirmed by the microdilution method accord-
ing to the Clinical Laboratory Standards Institute (CLSI)
guidelines.
Whole genome sequencing
Genomic DNAs were prepared from mid-log phase S.
pneumoniae cultures using the Wizard Genomic DNA
Purification kit (Promega, Madison, WI, USA) according
to the manufacturer’s instructions. The genome of the
R6M1 mutant was sequenced by using the NimbleGen
WGS approach [44]. Briefly, DNA from the R6M1
mutant and its progenitor were differentially labeled
with fluorescent markers and were co-hybridized on
DNA tiling microarrays. Regions hybridizing differently
were sequenced by a second round of sequencing hybri-
dization arrays. The sequencing and analysis were per-
formed by NimbleGen [20]. The genome of the R6M2
mutant was sequenced using the 454 Life Sciences
(Roche, Branford, FL, USA) GS-FLX system. The gen-
ome sequencing, assemblies, and comparative analysis
were performed at the McGill University Genome Que-
bec Innovation Center. The sequence of R6M2 is avail-
able at NCBI under the accession number PRJNA73471.
Mutations, deduced from either array hybridizations or
massively parallel sequencing, were confirmed by PCR
amplification and Sanger sequencing. A circular map of
the genome of R6M1 and R6M2 showing the identified
mutations is provided (Additional file 1).
DNA constructs
The genetic constructs used in this study are described
in Additional file 5. Gene inactivation was done by
insertional duplication mutagenesis using the nonrepli-
cative pFF3 and pFF6 plasmids. The pFF3 plasmid is a
pGEMT easy (Promega) derivative into which an
Eam1105I restriction site was introduced in the multiple
cloning site and the ampicillin resistance marker was
replaced by the chloramphenicol resistance marker of
pEVP3 [45] (a kind gift of D Morrison, University of Illi-
nois at Chicago). The pFF6 plasmid is a derivative of
pFF3 in which the chloramphenicol resistance marker
was replaced by the kanamycin marker of pDL289 [46]
(a kind gift of D Cvitkovitch, University of Toronto).
Fragments of the genes to be inactivated were amplified
from genomic DNA of S. pneumoniae R6 (Additional
file 4) and cloned into the multiple cloning sites of pFF3
or pFF6. The Janus cassette (a kind gift from D Morri-
son, University of Illinois, Chicago) was also used for
gene inactivation and gene replacement study in a strep-
tomycin-resistant background in S. pneumoniae as
described [21]. Janus is a 1.3-kb cassette with a kanamy-
cin resistance marker and a counterselectable rpsL
marker conferring streptomycin sensitivity. To generate
a streptomycin-resistant background, S. pneumoniae
strains were transformed with a rpsL
+ PCR fragment
that was amplified from chromosomal DNA of the
streptomycin-resistant strain CP1296 and the selection
was done on agar supplemented with 150 μg/ml of
streptomycin.
Genetic transformation
The penicillin-resistance phenotype was reconstructed
by transforming the penicillin-susceptible S. pneumoniae
R6 with PCR fragments amplified from the penicillin-
resistant R6M1 or R6M2 mutants (Additional file 4).
Selection was done on plates containing appropriate
concentrations of penicillin. Competent cells were
obtained by the dilution of an overnight S. pneumoniae
culture 1:100 in C+Y medium, pH 6.8 [47]. The diluted
cultures were grown up to the onset of exponential
phase before being concentrated ten times and frozen in
C+Y, pH 6.8, 15% glycerol. For transformation, compe-
tent cells were thawed on ice, diluted ten times with C
+Y medium, pH 7.8, and complemented with 2 μg/ml of
competence stimulating peptide 1 (csp-1) before being
incubated for 15 minutes at 35°C under a 5% CO2
atmosphere. DNA was added to a final concentration of
2 μg/ml and the cultures were incubated for 1 hour at
30°C. Finally, the cultures were switched to 35°C under
a5 %C O 2 atmosphere for 1 hour before being plated on
CAT medium containing the appropriate concentration
of antibiotic. The plates were incubated for 48 hours at
35°C under a 5% CO2 atmosphere and the resistant
colonies were picked for further studies.
Detection of reactive oxygen species
The intracellular ROS accumulation was measured using
the DCF-DA dye (Invitrogen, Grand Island, NY, USA)
whose fluorescence is proportional to the level of ROS
[48]. In a typical experiment, cells were grown to the
onset of exponential phase (OD600 0.12) before penicil-
lin, ciprofloxacin, kanamycin, chloramphenicol or tetra-
cycline were added at a final concentration of 0.1, 4.0,
400, 6.0 and 0.25 μg/ml, respectively. One milliliter ali-
quots were collected at baseline (prior to the addition of
antibiotic) and at 1, 2 and 3 hours following the addi-
tion of antibiotic. The aliquots were washed once and
resuspended in 500 μl of 1× PBS (pH 7.2) containing 5
μMD C F - D Aa n di n c u b a t e da t3 7 ° Ci nt h ed a r kf o r3 0
minutes. The labeled cells were washed once and resus-
pended in 500 μl of 1× PBS. The fluorescence signal of
a 200 μl aliquot was analyzed using a Victor fluorometer
(Perkin-Elmer, Waltham, MA, USA) at 485 nm excita-
tion and 535 nm emission wavelengths. Results are
expressed as relative fluorescence units (RFU) and were
normalized according to the number of live cells at each
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Page 10 of 12time point. A minimum of three independent experi-
ments have been performed for each antibiotic.
Additional material
Additional file 1: Circular maps of the genome of R6M1 and R6M2.
Additional file 2: Chronological appearance of PBP mutations
according to the levels of penicillin resistance in R6M2.
Additional file 3: PBP1a-targeting Janus cassette.
Additional file 4: Oligonucleotides used in this study.
Additional file 5: Plasmids used in this study.
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